Ameriprise Portfolio holdings
Ameriprise Financial, Inc., founded in 1894 as Investors Syndicate and headquartered in Minneapolis, Minnesota, is a leading financial services firm specializing in wealth management, financial planning, and insurance, managing hundreds of billions in assets for individual and institutional clients. Evolving from its roots in investment certificates, it now offers a comprehensive suite of services, including retirement planning, annuities, mutual funds, and advisory solutions, delivered through a network of over 10,000 financial advisors across the U.S. Known for its client-first approach, Ameriprise became independent in 2005 after spinning off from American Express, focusing on personalized advice and robust digital tools to compete in a crowded market. With a strong emphasis on long-term relationships and financial security, Ameriprise has grown into a trusted name in the retail investment and insurance sectors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$810M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$745M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$671M |
| 4 |
Boeing
BA
|
+$390M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$361M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$784M |
| 2 |
NVIDIA
NVDA
|
+$532M |
| 3 |
Apple
AAPL
|
+$491M |
| 4 |
Amazon
AMZN
|
+$438M |
| 5 |
Newmont
NEM
|
+$399M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.71% |
| 2 | Financials | 11.26% |
| 3 | Healthcare | 8.31% |
| 4 | Industrials | 8.25% |
| 5 | Consumer Discretionary | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3951
Savara
SVRA
$1.14B
| $37.3K | ﹤0.01% |
+12,139
| New | +$42.3K |
|
3952
Accuray
ARAY
$34M
| $35.2K | ﹤0.01% |
+17,760
| New | +$33.6K |
|
3953
Lightwave Logic
LWLG
$931M
| $35K | ﹤0.01% |
+16,650
| New | +$47.7K |
|
3954
Sibanye-Stillwater
SBSW
$6.43B
| $34.9K | ﹤0.01% |
+10,565
| New | +$44.5K |
|
3955
Pyxis Oncology
PYXS
$182M
| $34.7K | ﹤0.01% |
+22,251
| New | +$64.2K |
|
3956
Tango Therapeutics
TNGX
$4.49B
| $34.6K | ﹤0.01% |
+11,198
| New | +$52K |
|
3957
PMV Pharmaceuticals
PMVP
$60.3M
| $34.4K | ﹤0.01% |
22,807
-16,715
| -42% | -$26.5K |
|
3958
Gray Television
GTN
$417M
| $33.2K | ﹤0.01% |
+10,541
| New | +$49.2K |
|
3959
Ocugen
OCGN
$427M
| $30.2K | ﹤0.01% |
+37,545
| New | +$34.4K |
|
3960
Sana Biotechnology
SANA
$904M
| $28.8K | ﹤0.01% |
+17,641
| New | +$52.6K |
|
3961
Getty Images
GETY
$158M
| $28.4K | ﹤0.01% |
+13,160
| New | +$43K |
|
3962
Kaltura
KLTR
$206M
| $28.1K | ﹤0.01% |
+12,787
| New | +$23.3K |
|
3963
American Battery Technology Co
ABAT
$278M
| $27.5K | ﹤0.01% |
11,175
-1,100
| -9% | -$1.23K |
|
3964
Lyell Immunopharma
LYEL
$336M
| $24K | ﹤0.01% |
+1,874
| New | +$37.1K |
|
3965
Akebia Therapeutics
AKBA
$362M
| $22.7K | ﹤0.01% |
+11,966
| New | +$20.8K |
|
3966
Microvision
MVIS
$85.7M
| $22.3K | ﹤0.01% |
+17,028
| New | +$17.9K |
|
3967
Lineage Cell Therapeutics
LCTX
$277M
| $21.5K | ﹤0.01% |
42,878
+19,378
| +82% | +$14.2K |
|
3968
GrowGeneration
GRWG
$87.1M
| $20.9K | ﹤0.01% |
12,382
-9,492
| -43% | -$18.2K |
|
3969
LanzaTech
LNZA
$59.4M
| $20.1K | ﹤0.01% |
+147
| New | +$22.1K |
|
3970
Alector
ALEC
$180M
| $20K | ﹤0.01% |
10,586
-165,623
| -94% | -$623K |
|
3971
Wheels Up
UP
$217M
| $19.5K | ﹤0.01% |
+592
| New | +$24.9K |
|
3972
TherapeuticsMD
TXMD
$23.5M
| $19.3K | ﹤0.01% |
22,470
| – | – |
|
3973
ProKidney
PROK
$324M
| $19.1K | ﹤0.01% |
+11,319
| New | +$20.4K |
|
3974
CBAK Energy Technology Ltd
CBAT
$43.9M
| $18.8K | ﹤0.01% |
+20,000
| New | +$20K |
|
3975
SkinHealth Systems
SKIN
$87.6M
| $18.2K | ﹤0.01% |
+11,437
| New | +$18K |
|
Similar funds
Ameriprise's Q4 2024 Portfolio in Review
As of Q4 2024, Ameriprise held 4,210 positions worth $390B, down 0.05% from $390B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Ameriprise's Q4 2024 filing shows 290 new, 1,777 increased, 1,865 reduced and 140 closed positions. Its largest new stake was Primo Brands: 2,607,261 shares worth $80.2M. The largest sale was Elevance Health, an estimated $784M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- Ameriprise's largest Q4 2024 buy was Primo Brands: 2,607,261 shares worth $80.2M.
- Ameriprise added most to iShares Core US Aggregate Bond ETF in Q4 2024, an estimated $810M increase.
- Ameriprise's biggest Q4 2024 reduction was Elevance Health, cutting an estimated $784M.
- Ameriprise fully exited Primo Water Corporation in Q4 2024, selling an estimated $62.3M.
- Ameriprise's ten largest holdings make up 21% of its $390B portfolio in Q4 2024.
- Ameriprise opened 290 new positions and closed 140 in Q4 2024.
- Ameriprise's portfolio value fell 0.05% quarter-over-quarter to $390B.
Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.